Last reviewed · How we verify

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab

University of Helsinki · FDA-approved active Small molecule

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab is a Combination immunosuppressive and anti-TNF therapy Small molecule drug developed by University of Helsinki. It is currently FDA-approved for Rheumatoid arthritis, Inflammatory bowel disease. Also known as: Trexan, Salazopyrin, Oxiklorin, Prednison, Remicade.

This combination therapy suppresses inflammatory and immune responses through multiple mechanisms including methotrexate-induced immunosuppression, sulfasalazine's anti-inflammatory effects, corticosteroid action, and TNF-alpha inhibition via infliximab.

This combination therapy suppresses inflammatory and immune responses through multiple mechanisms including methotrexate-induced immunosuppression, sulfasalazine's anti-inflammatory effects, corticosteroid action, and TNF-alpha inhibition via infliximab. Used for Rheumatoid arthritis, Inflammatory bowel disease.

At a glance

Generic nameTrexan+Salazopyrin+Oxiklorin+prednisolone + infliximab
Also known asTrexan, Salazopyrin, Oxiklorin, Prednison, Remicade
SponsorUniversity of Helsinki
Drug classCombination immunosuppressive and anti-TNF therapy
TargetMultiple: dihydrofolate reductase (methotrexate), TNF-alpha (infliximab), glucocorticoid receptor (prednisolone)
ModalitySmall molecule
Therapeutic areaImmunology / Rheumatology
PhaseFDA-approved

Mechanism of action

Trexan (methotrexate) inhibits dihydrofolate reductase and suppresses T-cell proliferation. Salazopyrin (sulfasalazine) reduces intestinal inflammation and modulates immune function. Prednisolone is a corticosteroid that broadly suppresses inflammation. Infliximab is a TNF-alpha inhibitor monoclonal antibody that blocks a key pro-inflammatory cytokine. Together, these agents target multiple pathways in inflammatory and autoimmune disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab

What is Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab?

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab is a Combination immunosuppressive and anti-TNF therapy drug developed by University of Helsinki, indicated for Rheumatoid arthritis, Inflammatory bowel disease.

How does Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab work?

This combination therapy suppresses inflammatory and immune responses through multiple mechanisms including methotrexate-induced immunosuppression, sulfasalazine's anti-inflammatory effects, corticosteroid action, and TNF-alpha inhibition via infliximab.

What is Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab used for?

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab is indicated for Rheumatoid arthritis, Inflammatory bowel disease.

Who makes Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab?

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab is developed and marketed by University of Helsinki (see full University of Helsinki pipeline at /company/university-of-helsinki).

Is Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab also known as anything else?

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab is also known as Trexan, Salazopyrin, Oxiklorin, Prednison, Remicade.

What drug class is Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab in?

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab belongs to the Combination immunosuppressive and anti-TNF therapy class. See all Combination immunosuppressive and anti-TNF therapy drugs at /class/combination-immunosuppressive-and-anti-tnf-therapy.

What development phase is Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab in?

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab is FDA-approved (marketed).

What are the side effects of Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab?

Common side effects of Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab include Infection (including serious infections), Bone marrow suppression, Hepatotoxicity, Gastrointestinal disturbance, Immunosuppression-related complications.

What does Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab target?

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab targets Multiple: dihydrofolate reductase (methotrexate), TNF-alpha (infliximab), glucocorticoid receptor (prednisolone) and is a Combination immunosuppressive and anti-TNF therapy.

Related